| Name | Title | Contact Details |
|---|---|---|
David Nix |
Director Information Technology - Enterprise Architecture / Epic Technical Infrastructure | Profile |
Ralph Letizia |
Deputy Chief Information Security Officer | Profile |
Michael Erickson |
Chief Information Security Officer | Profile |
Harbor House Senior Residence is a Oyster Bay, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
one45 Software Inc. is a Creston, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Veran Medical Technologies, Inc., an image guided medical device company, develops a suite of products to enable physicians to diagnose disease and deliver therapies. It offers standards for minimally invasive delivery of interventional oncology therapies. The company provides plug-n-play delivery systems and navigated instruments. Its IG4 Platform allows clinicians to visualize various types of information integrated with a CT dataset, such as respiration, contrast enhanced structures, PET, and ultrasound. The company also provides SPiN Drive System that acts as a GPS-like system to enable pulmonologists and surgeons to access peripheral solitary pulmonary nodules to diagnose malignancy. Veran Medical Technologies, Inc. was incorporated in 2007 and is headquartered in St. Louis, Missouri.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
Roche Insulin Delivery Systems is a Fishers, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.